Matin Abdul, Chaudhry Gul-E-Saba, Azra Mohamad Nor, Gazali Mohamad, Yeong Yik Sung, Tengku Muhammad Tengku Sifzizul
Institute of Climate Adaptation and Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia.
Department of Food Processing and Engineering, Faculty of Food Science and Technology, Chattogram Veterinary and Animal Sciences University, Chattogram, Bangladesh.
Malays J Med Sci. 2024 Aug;31(4):14-34. doi: 10.21315/mjms2024.31.4.2. Epub 2024 Aug 27.
Atherosclerosis is characterised by the accumulation of fatty deposits and plaque as a result of a continuously high level of low-density lipoprotein cholesterol (LDL-C) in the blood. The primary objective of this research is to assess the current status of knowledge, research endeavours and developmental trajectories about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in correlation with atherosclerosis treatment. Additionally, this study aims to compile bibliometric and scientometric investigations within this domain through rigorous scientometric analysis. Analysing the bibliometric landscape and global research trends associated with PCSK9 inhibitors can contribute valuable insights into comprehending atherosclerosis. This is exemplified by examining publications within the Web of Science Core Collection (WOSCC) database from 2008 to 2022. Citespace was used for frequency, co-occurrence, co-citation, grouping and burst analysis, and Microsoft Excel was used to manage descriptive datasets. Eight hundred eighty-five publications available from WOSCC database between the years 2008 and 2022 were extracted and examined. Over the period, 3,138 collaborating institutions from 87 countries, a staggering 7,750 writers involved and 325 distinct journals published about PCSK9 inhibitors studies. Among authors, Sabatine et al. and the journal has had the most significant impact. Lipid-lowering therapy and bempedoic acid are the most prominent topical clusters associated with PCSK9 inhibitors, and the most often used keywords are efficacy, safety and PCSK9 inhibitors. We believe this is the first comprehensive analysis of PCSK9 inhibitors research and publications conducted using Scientometric. These results demonstrate the nascence of PCSK9 inhibitors research. They may encourage a wide range of stakeholders, particularly early career researchers from various disciplines, to work together in the future.
动脉粥样硬化的特征是由于血液中低密度脂蛋白胆固醇（LDL-C）持续处于高水平，导致脂肪沉积物和斑块的积累。本研究的主要目的是评估与动脉粥样硬化治疗相关的前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的知识现状、研究努力和发展轨迹。此外，本研究旨在通过严格的科学计量分析，在该领域内进行文献计量和科学计量研究。分析与PCSK9抑制剂相关的文献计量格局和全球研究趋势，可为理解动脉粥样硬化提供有价值的见解。以2008年至2022年Web of Science核心合集（WOSCC）数据库中的出版物为例进行研究。使用Citespace进行频率、共现、共被引、分组和突发分析，并使用Microsoft Excel管理描述性数据集。从WOSCC数据库中提取并检查了2008年至2022年间的885篇出版物。在此期间，来自87个国家的3138个合作机构、多达7750名作者参与其中，325种不同的期刊发表了关于PCSK9抑制剂的研究。在作者中，Sabatine等人以及该期刊产生的影响最为显著。降脂治疗和贝派地酸是与PCSK9抑制剂相关的最突出的主题集群，最常用的关键词是疗效、安全性和PCSK9抑制剂。我们认为这是首次使用科学计量学对PCSK9抑制剂研究及出版物进行的全面分析。这些结果表明PCSK9抑制剂研究尚处于起步阶段。它们可能会鼓励众多利益相关者，尤其是来自各个学科的早期职业研究人员，在未来共同合作。
